The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Ferring; ipsen; Janssen-Cilag; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Janssen-Cilag; Sanofi
Speakers' Bureau - Astellas Pharma; Astellas Pharma; AstraZeneca; Janssen-Cilag; Janssen-Cilag
Research Funding - AstraZeneca; AstraZeneca (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Ferring; Ipsen; Janssen-Cilag; Sanofi
 
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Novartis; Pfizer; Roche; Sanofi
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Pfizer; Roche
PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
 
Fred Saad
Honoraria - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bayer; BMS; Janssen Oncology; Knight Therapeutics; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Janssen Oncology; Knight Therapeutics; Myovant Sciences; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Andrew J. Armstrong
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Dendreon; FORMA Therapeutics; Janssen; Merck; Pfizer
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); FORMA Therapeutics (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc
 
Antoine Thiery-Vuillemin
No Relationships to Disclose
 
Mototsugu Oya
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Takeda
Consulting or Advisory Role - Bayer
Research Funding - Astellas Pharma
 
Eugenia Loredo
No Relationships to Disclose
 
Giuseppe Procopio
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb (BMS); Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer
 
Juliana Janoski De Menezes
No Relationships to Disclose
 
Gustavo Colagiovanni Girotto
Honoraria - MSD Oncology
Speakers' Bureau - MSD Oncology
Research Funding - BMS Brazil (Inst); MSD Oncology (Inst)
 
Cagatay Arslan
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; Novartis; Pfizer; Teva
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; Novartis; Pfizer; Teva
Research Funding - Amgen; AstraZeneca; Bristol-Myers Squibb; Henlius; Janssen; Lilly; Merck; Novartis; Roche; Yuhan
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; Merck; Novartis; Pfizer; Teva
 
Niven Mehra
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen-Cilag; MSD Oncology (Inst)
Research Funding - Astellas Pharma (Inst); Janssen-Cilag (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Janssen-Cilag; MSD Oncology; Roche
 
Francis Parnis
Consulting or Advisory Role - Ipsen; Janssen Oncology; Merck Serono
 
Emma Brown
No Relationships to Disclose
 
Friederike Schlürmann
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen; Pfizer
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen; MSD; Pfizer
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; MSD
 
Jae Young Joung
Honoraria - Astellas Pharma; Johnson & Johnson/Janssen; Sanofi/Aventis
 
Mikio Sugimoto
Honoraria - Astellas Pharma; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Kissei Pharmaceutical; Nippon Shinyaku; Novartis; Pfizer; Takeda
 
Christian Heinrich Poehlein
Employment - Merck
Leadership - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Chintu Desai
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Jinyu Kang
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Noel Clarke
No Relationships to Disclose